Hypercholesterolemia Dyslipidemia

Lipitor (Atorvastatin) Atherosclerosis Dyslipidemia Hypercholesterolemia 3.8 1.3 1997 - UK and US Once daily... 

The principal use of niacin is for mixed hyperlipidemia or as a second-line agent in combination therapy for hypercholesterolemia. It is a first-line agent or alternative for the treatment of hypertriglyceridemia and diabetic dyslipidemia. 

Hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson type I la and lib) - The dose range for rosuvastatin is 5 to 40 mg once daily. Individualize rosuvastatin therapy according to goal of therapy and response. The usual recommended starting dose of rosuvastatin... 

Hypercholesterolemia Adjunctive therapy to diet for the reduction of LDL-C, total-C, triglycerides, and apolipoprotein B (apo B) and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types lla and Mb). 

Primary hypercholesterolemia/mixed dyslipidemia For the treatment of primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types lla and Mb) in the following Patients treated with lovastatin who require further TG-lowering or FIDL-raising who may benefit from having niacin added to their regimen patients treated with niacin who require further... 

Rosuvastatin (Crestor) [Antilipemic/HMG-CoA Reductase Inhibitor] Uses Rx primary hypercholesterolemia mixed dyslipidemia ... 

Pravastatin is indicated as an adjunct to diet in patients with primary hypercholesterolemia, mixed dyslipidemia, elevated serum triglyceride levels and primary dysbetalipoproteinemia who do not respond adequately to diet. 

Indication Adjunct to diet for the reduction of elevated total cholesterol. LDL. apo B. and TG levels in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial). mixed dyslipidemia (Fredrickson types Ila and 1 lb), elevated TG (type IV) and primary dysbetali-poproteinemia (type III) Adjunct to other lipid lowering treatments for homozygous familial hypercholesterolemia ... 

Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In Brunton LL, et al, eds. The Pharmacological Basis of Therapeutics. 11th ed. New York McGraw-Hill 2006. 

Atorvastatin calcium is used as an adjunct to diet to reduce the elevated total-cholesterol, LDL, apolipoprotein B (apo B), and triglyceride (TG) levels, and to increase the HDL-C level in patients with primary hypercholesterolemia and mixed dyslipidemia. The drug is also used for the treatment of patients with an elevated serum TG levels, and for the patients with primary dysbetaliproteinemia, which do not respond adequately to diet. Atorvastatin calcium is also indicated to reduce the total-cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia (e.g., LDL apheresis) [6]. 

V6. Vega, G. L., Toto, R. D., and Grundy, S. M., Metabolism of low density lipoproteins in nephrotic dyslipidemia Comparison of hypercholesterolemia alone and combined hyperlipidemia. Kidney Int. 47,579-586 (1995). 

Hereditary dyslipidemias such as familial hypercholesterolemia, type II and type IV hyperlipidemia and Tangiers disease predispose to premature large vessel atherosclerosis and hence stroke (Meschia 2003 Hutter et al. 2004). 

Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998 32(10) 1030-43. 

Baycol was indicated as an adjunct to diet to reduce elevated total-cholesterol, low-density lipoprotein cholesterol (LDL-C), apo B, and triglycerides (TG) and to increase high-density lipoprotein cholesterol (HDL-C) levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types Ila and Ilb) when the response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures alone had been inadequate. Therapy with lipid altering drugs should bea component of multiple risk factor intervention in those patients at significantly high risk for atherosclerotic vascular disease due to hypercholesterolemia. 

Indications Hypercholesterolemia, Mixed dyslipidemia Category HMG-CoA reductase inhibitor Statin Half-life 19 hours... 

The manufacturer does not recommend use of the fixed combination as initial therapy of primary hypercholesterolemia or mixed dyslipidemia. It is specifically Indicated in patients receiving lovastatin alone plus diet who require an additional reduction in triglyceride levels or increase in HDL cholesterol levels it is also Indicated In those treated with niacin alone who require additional decreases in LDL cholesterol. 

Nissen, S.E., Nicholls, S.J., Wolski, K., Howey, D.C., McErlean, E., Wang, M..-D., Gomez, E.V. and Russo, J.M. (2007) Effects of a potent and selective PPAR-a agonist in patients with atherogenic dyslipidemia or hypercholesterolemia. Journal of the American Medical Association, 297, 1362-1373. 

Niacin, a B-complex vitamin, is used in the treatment of pellagra, peripheral vascular disease, and circulatory disorders, and as an adjunctive treatment of hyperlipidemias, especially those associated with hypercholesterolemia. Niacin, nicotinic acid (pyridine-3-carboxylic acid), is one of the oldest drugs used to treat dyslipidemia and favorably affects virtually all lipid parameters. 

Rosuvastatin is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor that inhibits HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol. It is indicated as an adjunct to diet to reduce elevated total cholesterol (C), LDL-C, non-HDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia as an adjunct to diet for the treatment of patients with elevated serum TG levels and to reduce LDL-C, total C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipidlowering treatments or if such treatments are not available. 

Pravastatin has been shown to increase levels of HDLC in patients with heterozygous familial and nonfamilial primary hypercholesterolemia and mixed dyslipidemia. as well as Frederickson Types 2a and 2b. 

---